Where does Depixus rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Depixus ranks #31,389 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Depixus hold?

Depixus holds 8 US utility patents granted between 2022 and 2025, spanning 3 technology areas.

What is Depixus's Innovation Score?

Depixus has an Innovation Score of 44.4 out of 100 (top 26% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Depixus's patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Depixus.

What does claim depth mean for Depixus's patents?

Depixus's patents average 17.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Depixus patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Depixus

Q: What technology areas does Depixus focus on?

Depixus's top technology area is C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes) with 4 patents, ranking #1,001 of 2,502 assignees active in that subclass. Grants appear in 3 CPC subclasses total.

USPTO PatentsView assignee record - 8 granted patents across 3 technology areas, recorded in grant years 2022–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Depixus ranks #31,389 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 3 technology areas.

#31,389
of 49,997 US assignees by volume: Top 26%
by Innovation Score (44.4/100): 17.9
avg claims per patent

USPTO PatentsView assignee plate

Corpus R31389 · Foreign Corporation #31,389 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 8 grants
MID-PACK #31,389/49,997
PHOTO-FINISH Del Mar Pharmaceutic…
CPC-NARROW C12Q · 3 areas
INNOV-PAR 44.4/100
CLAIMS-RICH 17.9 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2022–2025 · 4y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Del Mar Pharmaceuticals (BC) Limited (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Depixus’s 44.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.6 pts (17%) Velocity 20.0 pts (45%) Breadth 6.1 pts (14%) Claim depth 10.7 pts (24%)

Qualcomm Incorporated · highest

85
Depixus · this assignee

44
Kuka Systems · near

44
Pivotal Commware · near

44
Qeexo · near

44
Tokyo Metropolitan… · near

44
3D Lighting… · lowest

7

What this shows Depixus's Innovation Score is 44.4/100 (top 26% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Depixus?

Each dot is one of Depixus’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Depixus’s own 17.9 claims/patent is ABOVE the 16.4 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Depixus vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Depixus's grants concentrate

Depixus is a focused PatentsView assignee: 3 CPC subclasses with 50% of grants classified under C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr). Peak complete grant year is 2022 (3 grants) versus a trough of 2 in 2024. By volume, Depixus sits between Del Mar Pharmaceuticals (BC) Limited and Dextera Surgical.

Depixus's three-year grant acceleration

Depixus shows 5 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Del Mar Pharmaceu…

8
Delca

8
Delcam

8
Deltran Operation…

8
Deuteria Beverages

8
Devmar Products

8
Devicescape Softw…

8
Dextera Surgical

8
Depixus ◀

8

What this shows Depixus holds 8 patents at rank #31,439, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Depixus

By rank, the assignees closest to #31,439 in granted patent volume.

Leaders in C12Q (Measuring OR Testing Processes Involving Enzymes)

Other assignees with the most granted patents in Depixus's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Depixus, neither rank-band nor same-CPC leaders (those blocks stay above). In C12Q (Measuring OR Testing Processes Involving Enzymes), Depixus ranks #1,001 of 2,502 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (44 here).

Kuka Systems GmbH 44 Qeexo, Co. 44 Tokyo Metropolitan University 44 Pivotal Commware, Inc. 44

Depixus's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

44 Top 26% higher than 74% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2022–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.

View data table

Depixus patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2022	3	37.5%
2024	2	25.0%
2025partial year	3	37.5%

Which technologies does Depixus patent most?

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 4

G02B - Optical Elements, Systems OR Apparatus 4

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 2

Top 3 of 3 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Depixus's patent record in context - here's where to go next.

Depixus's lead technology class is C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr), 50% of its portfolio - see every assignee active in that class. Explore C12Q
Ranked #31,389 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Depixus against Del Mar Pharmaceuticals (BC) Limited, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 44.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.